Future options for therapies to limit damage and enhance recovery

Seminars in Neurology

Volumn 18, Issue 3, 1998, Pages 405-414

  Compston, Alastair ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cytokines; Growth factors; Microglial monoclonal antibodies; Oligodendrocytes; Pathogenesis; T cells; Transplantation

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MONOCLONAL ANTIBODY; NEUROTROPHIN; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN; THYROXINE; TUMOR NECROSIS FACTOR ALPHA;

CENTRAL NERVOUS SYSTEM; DISEASE COURSE; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MICROGLIA; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; OLIGODENDROGLIA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT PLANNING;

EID: 0031793927     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1040890     Document Type: Review

References (81)

1. Moreau T, Hale G, Waldmann H, et al. Cytokine release increases conduction block in partially demyelinated pathways due to multiple sclerosis. Brain 1996;119:235-237
2. Redford EJ, Kapoor R, Smith KJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997;120:2149-2157
3. Youl BD, Turano G, Miller DH, et al. The pathophysiology of acute optic neuritis: an association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991;114:2437-2450
4. Hall G, Compston DAS, Scolding NJ 1997 β-interferon and multiple sclerosis. Trends Neurosci 1997;20:63-67
5. Zajicek, JP, Wing M, Scolding NJ, Compston DAS. Interactions between oligodendrocytes and microglia, a major role for complement and tumour necrosis factor in oligodendrocyle adherence and killing. Brain 1992;115:1611-1631
6. England JD, Gamboni F, Levinson SR, Finger TE. Changed distribution of sodium channels along demyelinated axons. Proc Nat Acad Sci USA 1990;87:6777-0780
7. Rivera-Quinones C, MacGavern D, Schmelzer JD, Hunter SF, Low PA, Rodriguez M 1998 Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat Med 1998;4:187-193
8. Prineas JW, Barnard RO, K won EE, Sharer LR, Cho E-S. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993; 33:137-151
9. Charcot JM. Histologic de la sclerose en plaques. Gazette Hopital (Paris) 1868;41:554-555; 557-558; 566
10. Ozawa K, Suchanek G, Breitschopf H, et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994;117:1311-1322
11. Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995;118:1583-1592
12. Mathews PM, Pioro E, Narayan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996;119:715-722
13. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-399
14. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Eng] J Med 1998;338:278-285
15. Barres BA, Raff MC. Proliferation of oligodendrocyte precursor cells depends on electrical activity in axons. Nature 1993;361:258-260
16. Colello RJ, Devey RL, Imperato E, Pott U. The chronology of oligodendrocyte differentiation in the rat optic nerve: Evidence for a signalling step initiating myelination in the CNS. J Neurosci 1995;15:7665-7672
17. Meyer-Franke A, Kaplan MR, Pfeiger FW, Barres BA. Characterisation of the signalling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron 1995;15:805-819
18. Sanches T, Hassinger L, Paskevich PA, et al. Oligodendroglia regulate the regional expansion of axon calibre and local accumulation of neurofilaments during development independent of myelin formation. J Neurosci 1996;16:5095-5105
19. Hohlfeld R. Biotechnical agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives (review). Brain 1997;120:865-916
20. Archelos JJ, Hartung H-P. The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications. Mol Med Today 1997;3:10-321
21. Yednock TA, Cannon C, Fritz LC, Sánchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against a4b1 integrin. Nature 1992;356:63-66
22. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon β-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-852
23. Stuve O, Dooley NP, Uhm JH, et al. Interferon β-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853-863
24. Corsini E, Gelati M, Dufour A, et al. Effects of β-interferon-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: An in vivo and in vitro study. J Neuroimmunol 1997;79:76-83
25. Stuve O, Chabot S, Jung SS, Williams G, Yong VW Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon β-1b through an effect on matrix metalloproteinase-9. J Neuroimmunol 1997;80:38-46
26. Lindsey JW, Hodgkinson S, Mehta R, et al. Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology 1994;44:413-419
27. Lindsey JW, Hodgkinson S, Mehta R, et al. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann of Neurol 1994;36:183-189
28. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody CM-T412; results of a randomised, double-blind, placebo-controlled, MR monitored phase II trial. Neurology 1997;49: 351-357
29. Moreau T, Thorpe J, Miller D, et al. Reduction in new lesion formation in multiple sclerosis following lymphocyte depletion with CAMPATH-IH. Lancet 1994;344:298-301
30. Fassas A, Anagnostopolous A, Kasis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: First results of a pilot study. Bone Marrow Transplant 1997;20:631-638
31. Burt RK, Burns RK, Miller SD. Bone marrow transplantation for multiple sclerosis: returning to Pandora's box. Immunol Today 1997;18:559-561
32. Zhang J, Medaer R, Sunsson P, et al. MHC restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 1993;261:1451-1454
33. Medaer R, Stinissen P, Truyen L et al. Depletion of myelin basic protein autoreactive T cells by T cell vaccination: Pilot trial in multiple sclerosis. Lancet 1995;346:807-808
34. Vandenbark AA, Chou YK, Whitham R, et al. Treatment of multiple sclerosis with T cell receptor peptides: Results of a double-blind pilot trial. Nat Med 1996;2:1109-1115
35. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerisation with myelin antigens in multiple sclerosis. Science 1993;259:1321-1324
36. Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral depletion of antigen-reactive T cells in oral tolerance. Nature 1995;376:177-180
37. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-1276
38. Wraith DC. Induction of antigen-specific unresponsiveness with synthetic peptides: Specific immunotherapy for treatment of allergic and autoimmune conditions. Int Arch Allerg Immunol 1995;108:355-359
39. Ludwin SK. Central nervous system demyelination and remyelination in the mouse. Lab Invest 1978;39:597-612
40. Komoly S, Hudson LD, deF Webster H, Bondy CA 1992 Insulin-like growth factor 1 gene expression is induced in astrocytes during experimental demyelination. Proc Nat Acad Sci 1992;89:1894-1898
41. Yao D-L, Liu X, Hudson LD, Webster H deF. Insulin-like growth factor 1 treatment reduces demyelination and up-regulates gene expression of myelin related proteins in experimental autoimmune encephalomyelitis. Proc Nat Acad Sci USA 1995;92. 6190-6194
42. Schlorlemmer HU, Seiler FR. 15-Deoxyspergulin (15-DOS) for therapy in an animal model of multiple sclerosis (MS): Disease modifying activity on acute and chronic relapsing experimental allergic encephalomyelitis (EAE). Agents Actions 1991;34:156-160
43. Kappos L, Radu EW, Haas J, Hartard CH, Harrung HP. European multicenter trial of deoxyspergualin (DSG) versus placebo, results of the first interim analysis. J Neurol 1994;241 (suppl 1): S27
44. Myers LW, Ellison GW, Merrill JE, et al. Pentoxyfilline not a promising treatment for multiple sclerosis. Neurology 1995; 45(suppl 4):A419
45. van Oosten EW, Rep MHG, van Lier RAW, et al. A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. J Neuroimmunol 1996;66:49-55
46. Rieckmann P, Weber F, Gunther A et al. Pentoxyfilline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunology 1996;64:193-200
47. Groves AK, Barnett SC, Franklin RJM, et al. Repair of demyelinated lesions by transplantation of purified O-2A progenitor cells. Nature 1993;362:453-455
48. Smith KJ, Blakemore WF, McDonald WI. The restoration of conduction by central remyelination Brain 1981;104:383-404
49. Jeffery ND, Blakemore WF. Locomotor deficits induced by experimental spinal cord demyelination are abolished by spontaneous remyelination. Brain 1997;120:27-37
50. Kiersted HS, Blakemore WF. Identification of post mitotic oligodendrocytes incapable of remyelination within the demyelinated adult spinal cord. J Neuropathol Exp Neurol 1997;56: 1191-1201
51. Kiersted HS, Levine JM, Blakemore WF. Response of the oligodendrocyte progenitor cell population (defined by NG2 labelling) to demyelinarion of the adult spinal cord. Glia 1998;22:161-170
52. Carroll WM, Jennings AR. Early recruitment of oligodendrocyte precursors in CNS demyelination. Brain 1994;117:563-578
53. Carroll WM, Jennings AR, Ironside LJ. Identification of the adul resting progenitor cell by autoradiographic tracking of oligodendrocyte precursors in experimental CNS demyelination. Brain 1998;121:293-302
54. Rodriguez M, Lennon VA, Benviste EN, Merrill JE. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J Neuropathol Exp Neurol 1987;46:84-95
55. Asakura K, Pogulis RJ, Pease LR, Rodriguez M. A monoclonal auloantibody which promotes central nervous system remyelination is highly polyreactive to multiple known and novel antigens. J Neuroimmunol 1996;65:11-19
56. Rodriguez M, Miller DJ, Lennon VA. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996;46:538-545
57. Rodriguez M, Lindsley MD. Immunosuppression promotes CNS remyelination in chronic virus-induced demyelinating disease. Neurology 1992;42:348-357
58. Fazekas F, Deisenhammer K, Strasser-Fuchs S et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349:589-593
59. Weidenheim KM, Epshteyn I. Rashbaum WK, Lyman WD. Patterns of glial development in the human foetal spinal cord during the late first and second trimester J Neurocytol 1994;23: 343-353
60. Yu WP, Collarini EJ, Pringle NP, Richardson WD. Embryonic expression of myelin genes: Evidence for a focal source of oligodendrocyte precursors in the ventricular zone of the neural tube. Neuron 1994;12:1353-1362
61. Hajihosseini M, Tham TN, Dubois-Dalcq M. Origin of oligodendrocytes within the human spinal cord. J Neurosci 1996;16: 7981-7994
62. Rivkin MJ, Flax J, Mozell R, et al. Oligodendroglial development in human fetal cerebrum. Ann Neurol 1995;38:92-101
63. Armstrong RC, Dorn HH, Kufta CV, et al. Pre-oligodendrocytes from adult human CNS. J Neurosci 1992;12:1538-1547
64. Gogate N, Verma L, Min Zhau J et al. Plasticity in the adult human oligodendrocyte lineage. J Neurosci 1994;14:4571-4587
65. Scolding NJ, Rayner PJ, Sussman J, et al. A proliferative adult human oligodendrocyte progenitor. NeuroReport 1995;6:441-445
66. Muir D, Compston DAS 1996 Growth factor stimulation triggers apopotic cell death in mature rat oligodendrocytes. J Neurosci Res 44:1-11
67. Casaccia-Bonnefil P, Carter BD, Dobrowsky RT, Chao MV. Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. Nature 1996;383: 716-719
68. Wood PM, Bunge RP. Myelination of cultured dorsal root ganglion neurons by oligodendrocytes obtained from adult rats. J Neurol Sci 1986;74:153-169
69. Ludwin SK, Szuchel S. Myelination by mature ovine oligodendrocytes in vivo and in vitro: Evidence that different steps in the myelinalion process are independently controlled. Glia 1993;8: 219-231
70. Shaw CE, Milner RM, Compston DAS, ffrench Constant C. Integrin expression during axo-glial interactions: a developmental comparison of oligodendrocytes and Schwann cells. J Neurosci 1996;16:1163-1172
71. Whittemore SR, Sanon HR, Wood PM. Concurrent isolation and characterisation of oligodendrocytes, microglia and astrocytes from adult human spinal cord. Int J Dev Neurosci 1993;11: 755-764
72. Franklin RJM, Crang AJ, Blakemore WF. Transplanted type-1 astrocytes facilitate repair of demyelinating lesions by host oligodendrocytes in adult rat spinal cord. N NEurocytol 1991;20: 420-430
73. Wood PM, Bunge RP. The origin of remyelinating cells in the adult central nervous system: The role of the mature oligodendrocyte. Glia 1991;4:225-232
74. Almazan G, McKay R. An oligodendrocyte precursor cell line from rat optic nerve. Brain Res 1992;579:234-245
75. Kitchens DL, Snyder EY, Gottlieb DI. FGF and EGF are mitogens for immortalized neural progenitors. J Neurobiol 1994;25:797-807
76. Avellana-Adalid V, LaChapelle G, Rougon A, Baron van Evercooren A. Expansion of rat O-2A glial progenitors into proliferative oligospheres that retain their myelinating capacity after transplantation into the shiverer newborn mouse brain [abstract]. Soc Neurosci 1994;20:885
77. Franklin RJM, Bayley SA, Blakemore WF. Transplanted CG-4 cells (an oligodendrocyte progenitor cell line) survive, migrate and contribute to repair of areas of demyelination in X-irradiated and damaged spinal cord but not in normal spinal cord. Exp Neurol 1996;137:263-276
78. Targett MP, Sussman J, Scolsing NJ, et al. Failure to remyelinate rat axons following transplantation of glial cells obtained from the adult human brain. Neuropathol Appl Neurobiol 1996;22: 199-206
79. Gumpel M, Lachapelle F, Gansmuller A, Baulac M, Baron-Van Evercooren A, Baumann N 1987 Transplantation of human embryonic oligodendrocytes into shiverer brain. Ann NY Acad Sci 1987;495:71-85
80. Seilhean D, Gansmuller, A Baron-van Evercooren, Gumpel M, Lachapelle F. Myelination by transplanted human and mouse central nervous system tissue after long-term cryopreservation. Acta Neuropathol 1996;91:82-88
81. Compston DAS. Remyelination in multiple sclerosis: A challenge for therapy. The Charcot lecture: European Charcot Foundation. J Multiple Sclerosis 1996;3:51-70